Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: L01CD01

Apealea(paclitaxel)

Ovarian Neoplasms

Marketing Authorisation Holder: Inceptua AB

EMA Authorisation: 20/11/2018

INN: paclitaxel

Indication

Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum?sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Apealea — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.